[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 124,704,544
  • Shares Outstanding, K 253,805
  • Annual Sales, $ 12,001 M
  • Annual Income, $ 3,953 M
  • EBIT $ 4,681 M
  • EBITDA $ 4,891 M
  • 60-Month Beta 0.30
  • Price/Sales 10.15
  • Price/Cash Flow 27.04
  • Price/Book 6.24

Options Overview Details

View History
  • Implied Volatility 29.95% (+0.91%)
  • Historical Volatility 25.36%
  • IV Percentile 50%
  • IV Rank 32.58%
  • IV High 46.24% on 02/12/26
  • IV Low 22.08% on 08/27/25
  • Expected Move (DTE 5) 7.28 (1.48%)
  • Put/Call Vol Ratio 0.89
  • Today's Volume 6,172
  • Volume Avg (30-Day) 2,216
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 41,849
  • Open Int (30-Day) 48,984
  • Expected Range 484.06 to 498.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 34 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $4.25
  • Number of Estimates 6
  • High Estimate $4.47
  • Low Estimate $3.98
  • Prior Year $4.00
  • Growth Rate Est. (year over year) +6.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
420.01 +16.98%
on 06/03/26
503.89 -2.49%
on 06/26/26
+55.41 (+12.71%)
since 05/26/26
3-Month
412.27 +19.18%
on 05/05/26
503.89 -2.49%
on 06/26/26
+37.60 (+8.29%)
since 03/26/26
52-Week
362.50 +35.54%
on 08/11/25
507.92 -3.26%
on 03/10/26
+47.94 (+10.81%)
since 06/26/25

Most Recent Stories

More News
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

IBB : 187.36 (+2.01%)
VRTX : 491.34 (+2.32%)
GILD : 127.88 (+3.26%)
AMGN : 358.33 (+1.56%)
3 of Wall Street’s Favorite Stocks to Consider Right Now

3 of Wall Street’s Favorite Stocks to Consider Right Now

SYK : 332.71 (+5.25%)
VRTX : 491.34 (+2.32%)
CASH : 87.16 (+0.39%)
2 Reasons to Like VRTX (and 1 Not So Much)

2 Reasons to Like VRTX (and 1 Not So Much)

VRTX : 491.34 (+2.32%)
3 Market-Beating Stocks Worth Investigating

3 Market-Beating Stocks Worth Investigating

TPC : 79.53 (-2.49%)
VRTX : 491.34 (+2.32%)
FAST : 47.10 (+0.38%)
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions

- Data from pivotal studies of CASGEVY in children ages 5–11 with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrate transformative potential in younger patients, consistent...

VRTX : 491.34 (+2.32%)
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of

VRTX : 491.34 (+2.32%)
Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the Goldman Sachs 47th Annual Global Healthcare Conference. Dr. Reshma Kewalramani, President and...

VRTX : 491.34 (+2.32%)
Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?

Despite Vertex Pharmaceuticals' underperformance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

XLV : 160.34 (+3.03%)
VRTX : 491.34 (+2.32%)
REGN : 632.90 (+2.06%)
AMGN : 358.33 (+1.56%)
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

- FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026 –

VRTX : 491.34 (+2.32%)
Is Regeneron Pharmaceuticals Stock Underperforming the Dow?

Regeneron Pharmaceuticals has underperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.

VRTX : 491.34 (+2.32%)
$DOWI : 51,876.11 (-0.09%)
REGN : 632.90 (+2.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which...

See More

Key Turning Points

3rd Resistance Point 524.44
2nd Resistance Point 514.17
1st Resistance Point 502.75
Last Price 491.34
1st Support Level 481.06
2nd Support Level 470.79
3rd Support Level 459.37

See More

52-Week High 507.92
Last Price 491.34
Fibonacci 61.8% 452.37
Fibonacci 50% 435.21
Fibonacci 38.2% 418.05
52-Week Low 362.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.